The Clinical Value Of High-risk Human Papilloma Virus Testing To Cervical Cancer

Objective: Cervical cancer is the most common gynecologic malignanttumor, its incidence in women’s second malignant tumor. According tostatistics all over the world, there are about466000new cases of cervicalcancer.80%of them will take place in developing countries.Now that the occurrence and development of cervical cancer is fromquantitative change to qualitative change, by the gradient on the long-termprocess of mutation. So the effective screening and appropriate intervention,can block it to the progress of cervical cancer, so as to reduce the morbidityand mortality of cervical cancer. Due to the widespread application of cervicalcytology in recent40years, early detection and treatment to the cervicallesions and cervical cancer before the incidence and mortality of cervicalcancer has declined obviously. But the cervical cytology have limitations.A lot of epidemiology and etiology researches have been clear about thetype of high-risk human papilloma virus persistent infection for cervicalcancer lesions and cervical cancer occurrence root cause before. So the HPVtesting can be used as screening for cervical cancer lesion before and one ofthe important means of cervical cancer. This experiment by comparing thecervical liquid thin-layer cytology (TCT) was studied with HPV TCTscreening of cervical lesions and cervical cancer detection rates, provide morevaluable for clinical screening for cervical cancer screening method, so as todo about cervical cancer early detection, early intervention, reduce theincidence and mortality. Study of HPV types and the correlation of the cervicallesion, provide reference for clinical follow-up and curative effect monitor.Methods:Choose outpatient women have sexual life in June2013to December2013, hebei medical university second hospital of obstetrics and gynecology,Randomly divided into two groups, Group A (TCT) using the thin liquid layer production method for screening of cervical lesions, Report according to theTBS classification, positive significance of atypical squamous cells (ASC-US)and the above judgment is positive, colposcope examination. Group B withCobas4800high-risk type HPV detection line of TCT detection at the sametime, the HPV positive and (or) TCT report was colposcope examination,when necessary, take the cervical biopsy, with histopathologic diagnosis as thegold standard.Results:11235cases of group A, TCT masculine gender, colposcopy cervical biopsy in136cases.Among them,92cases of chronic cervicitis, CINI25examples, CINII13examples, CINIII6examples, TCT detection rate of32.35%of cervical lesions.6387cases of Group B, HPV positive for704cases,283cases of TCT positie, take cervical biopsy under colposcope send pathology with243cases, with83cases of chronic cervicitis,CINI59examples, CINII57examples, CINIII40cases,4cases of cervical cancer and HPV joint TCT of cervical lesion detection rate was65.84%, the detection rate of the two groups are significant differences (P<0.05).2Group B in the high-risk type HPV morbidity of cervical lesions subtypeHPV16infection,65.38%(51/78) respectively, and the subtype HPV18infection,84.21%(16/19),63.41%(59/93), the rest12types of HPV infectionmixed infection68%(34/50), including subtype HPV16and HPV18subtypesand mixed infection of pathogenic rate had no statistical difference (P>0.05).HPV16subtype and the rest of the12kinds of pathogenic rate was statisticallydifference (P <0.05), HPV18subtype and the mixed infection of pathogenicrate no significant statistical difference (P>0.05), but compared with the restof the12kinds of pathogenic rate have significant statistical difference (P <0.05), the remaining12and mixed infection of pathogenic rate alsostatistically significant (P <0.05). Rate of high risk type HPV cause height ofcervical lesions (including CINII and CINIII) was statistically difference (P <0.05). 3Cervical lesions in the distribution of HPV subtypes have statisticaldifference (P <0.05). CINIII HPV16and (or) in18patients was93.75%(15/16), CINII HPV16and18patients (92.68%),(or) CINI HPV16and (or) in18patients (66.67%), the other12patients (33.33%)Conclusion：1It can obviously improve the detection rate, decrease the missed diagnosiswith TCT and HPV screening for cervical pathological changes. So theclinical application of HPV screening joint TCT for cervical lesions andcervical cancer, can be better for cervical cancer early detection, earlyintervention, so as to further reduce the morbidity and mortality of cervicalcancer. Effectively prevent the occurrence of cervical cancer.2CINI is mainly related to the rest12types of HPV infection, CINII andCINIII mainly associated with HPV16,18.